FDA approves first immunotherapy regimen for breast cancer

The US Food and Drug Administration has granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday. (CNN Photo)

The US Food and Drug Administration has granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday.

Posted: Mar 9, 2019 10:17 AM

(CNN) -- The US Food and Drug Administration has granted its first approval to an immunotherapy regimen for breast cancer, the agency announced Friday.

The treatment received accelerated approval for triple-negative breast cancer that is locally advanced or metastatic, that cannot be surgically removed and whose cells include a protein called PD-L1. It comprises a combination of immunotherapy and chemotherapy: Tecentriq and Abraxane, respectively.

The FDA's decision comes after an October study published in the New England Journal of Medicine found that the therapy extended progression-free survival -- the amount of time in which a patient's cancer does not worsen. In the PD-L1 subgroup, the median progression-free survival for those receiving the combination treatment was 7.4 months, versus 4.8 months for those getting the chemotherapy with placebo, according to the FDA's announcement. The trial was funded by Genentech Inc., the maker of Tecentriq.

"This is the first time immunotherapy has worked in such a difficult to treat cancer, and is a huge step forward for these breast cancer patients," lead study author Dr. Peter Schmid of Queen Mary University of London said in an October statement.

Dr. Otis Brawley, Bloomberg Distinguished Professor of oncology and epidemiology at Johns Hopkins University, said the FDA's decision to grant the treatment accelerated approval was "the right thing to do" but cautioned that it's not the end of the story.

"The FDA has approved it based on progression-free survival with the hope that later on ... data will show that the treatment actually makes women live longer," said Brawley, who was not involved in researching the treatment.

This FDA says it grants accelerated approvals to "drugs that treat serious conditions, and that fill an unmet medical need" based on data that suggests, but may not directly measure, a clinical benefit. Drugmakers are still required to confirm that the drug is beneficial through later trials. If that happens, the drug may receive a traditional FDA approval. Otherwise, the agency may decide to pull the drug, as has happened in the past.

In this case, the drugmaker is expected to submit a final report detailing subsequent findings in September 2020, according to the approval letter from the FDA to Genentech.

Tecentriq, the brand name of the immunotherapy drug atezolizumab, was previously approved to treat other specific types of urinary and lung cancers.

Breast cancer patients on the newly approved therapy most commonly reported adverse reactions like hair loss, fatigue, nausea, headaches and decreased appetites, according to the FDA.

Dr. Larry Norton, director of the Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center, told CNN in October that scientists are learning "so much and so rapidly about other ways to stimulate the immune system" that he predicts an "explosion of well-designed studies that will push the agenda forward."

Norton, who was not involved in the October study, said "this is just the beginning of using immunotherapy for breast cancer."

Triple-negative breast cancer
About 15% of breast cancers are triple-negative, according to the National Breast Cancer Foundation. The protein PD-L1 may be found in roughly a fifth of those cancers, research has shown.

Triple-negative breast cancer is most likely to affect Hispanic and African-American women and those with a BRCA1 gene mutation. It also tends to appear among women in their 40s and 50s.

"It is particularly tragic that those affected are often young," Queen Mary University's Schmid said. "We have desperately been looking for better treatment options."

When breast cancer cells test negative for estrogen, progesterone or human epidermal growth factor 2 (HER2), it's called a triple-negative breast cancer. Therefore, it does not respond to any of the available hormonal cancer treatments.

It does respond to chemotherapy. However, cancer cells can quickly develop resistance to chemo drugs, allowing them to spread to other parts of the body, reducing survival rates.

How does it work?
Cancers have a way of eluding the body's immune system, which recognizes them as part of the body. That's where Tecentriq comes in: It's an antibody that attaches to the cancer cell and inactivates the PD-L1 protein, which is responsible for telling the immune system, "don't attack me."

Chemotherapy is also needed to "rough up" the exterior of the cancer cell, Schmid explained. That allows the newly revved-up immune system to recognize and attack the invader.

"We are using chemotherapy to tear away the tumor's 'immune-protective cloak,' to expose it," Schmid said, "enabling people's own immune system to get at it."

Norton said in October that "I think the expectation is, this will change the standard of care.

"This is a real advance that is going to allow us to help more people."

Terre Haute
Clear
90° wxIcon
Hi: 92° Lo: 70°
Feels Like: 96°
Robinson
Clear
88° wxIcon
Hi: 90° Lo: 68°
Feels Like: 95°
Indianapolis
Broken Clouds
89° wxIcon
Hi: 92° Lo: 70°
Feels Like: 94°
Rockville
Clear
85° wxIcon
Hi: 90° Lo: 70°
Feels Like: 88°
Casey
Clear
87° wxIcon
Hi: 90° Lo: 70°
Feels Like: 91°
Brazil
Clear
90° wxIcon
Hi: 91° Lo: 70°
Feels Like: 96°
Marshall
Clear
90° wxIcon
Hi: 91° Lo: 70°
Feels Like: 96°
Hot and Humid 4th of July
WTHI Planner
WTHI Temps
WTHI Radar

WTHI Events

 

Illinois Coronavirus Cases

(Widget updates once daily at 7 p.m. CT)

Confirmed Cases: 145750

Reported Deaths: 7005
CountyConfirmedDeaths
Cook917744618
Lake9864421
DuPage9192474
Kane7796274
Will6839320
Winnebago306796
McHenry208897
St. Clair1965137
Kankakee130265
Rock Island99629
Madison99169
Kendall98121
Champaign93012
Boone60221
DeKalb56719
Peoria54628
Sangamon44032
Jackson33519
Randolph2877
Stephenson2755
Ogle2684
McLean26713
Clinton24017
Macon23222
LaSalle22417
Union19319
Whiteside19215
Coles17317
Grundy1695
Iroquois1605
Tazewell1468
Warren1430
Knox1360
Cass1346
Morgan1303
Monroe12913
Williamson1224
Adams1061
Jefferson10617
McDonough10215
Lee982
Henry931
Vermilion772
Pulaski760
Marion680
Perry561
Douglas540
Macoupin543
Livingston502
Jasper477
Jo Daviess461
Montgomery461
Unassigned460
Christian454
Ford371
Jersey351
Woodford342
Bureau292
Franklin270
Menard240
Fayette233
Alexander220
Carroll222
Mason220
Wabash220
Mercer210
Piatt210
Washington210
Johnson200
Hancock191
Moultrie190
Shelby191
Crawford180
Logan160
Clark150
Fulton150
Massac150
Wayne141
Bond131
Effingham131
Schuyler130
Cumberland120
Brown100
Edgar100
De Witt90
Greene90
Marshall90
Saline90
Henderson80
Lawrence70
White60
Hamilton50
Richland40
Stark40
Pike30
Clay20
Edwards20
Gallatin20
Calhoun10
Hardin10
Pope10
Putnam10
Scott10
Out of IL00

Indiana Coronavirus Cases

(Widget updates once daily at 8 p.m. ET)

Confirmed Cases: 46915

Reported Deaths: 2681
CountyConfirmedDeaths
Marion11499683
Lake5053242
Elkhart316443
Allen2717128
St. Joseph186366
Cass16369
Hamilton1518100
Hendricks1386100
Johnson1254118
Porter71237
Tippecanoe6778
Madison64864
Clark63844
Bartholomew58244
Howard56057
LaPorte55326
Kosciusko5124
Vanderburgh4806
Jackson4653
LaGrange4657
Noble45728
Hancock43735
Boone43443
Delaware42949
Marshall4273
Shelby42025
Floyd37144
Morgan32531
Montgomery29320
Grant29026
Clinton2852
Monroe26628
Dubois2646
White26010
Decatur24832
Henry24315
Lawrence23624
Vigo2288
Dearborn22723
Harrison21022
Warrick21029
Greene18432
Miami1812
Jennings17111
Putnam1688
Scott1607
DeKalb1594
Daviess14116
Orange13523
Wayne1346
Perry1279
Steuben1262
Franklin1248
Jasper1142
Ripley1147
Carroll1102
Wabash1102
Fayette987
Newton9710
Whitley884
Starke853
Randolph784
Huntington712
Wells711
Jefferson701
Fulton681
Jay680
Washington661
Knox630
Pulaski621
Clay604
Gibson592
Rush563
Adams481
Benton480
Owen471
Sullivan441
Brown381
Blackford372
Posey360
Spencer351
Fountain302
Tipton301
Crawford290
Switzerland260
Martin220
Parke220
Ohio140
Warren141
Union130
Vermillion130
Pike90
Unassigned0193